CompBrief BY VELARION

Companies Catalent, Inc.

Catalent CEO salary & total pay, FY2023: $6.6M

Catalent (CLT) CEO salary, fiscal 2023: Alessandro Maselli was paid a salary of $925,000 and $6,583,672 in total compensation. Free brief. Every figure links to the company’s own filing.

Catalent, Inc. no longer files a proxy statement; its last pay data is FY2023.

All products and prices

Alessandro Maselli's complete compensation dossier

A PDF and a CSV sent to your email: Alessandro Maselli's pay in every fiscal year Catalent, Inc. reported it, line by line, with Alessandro Maselli's equity grants and Catalent, Inc.'s disclosed peer group where the company discloses them. Every row is cited to its filing.

One-time report. No refunds.

See an example →
CEO total pay$6,583,672CEO Alessandro Maselli · source
Say-on-pay support97.01%Latest vote · source
CEO vs. named peers1st pct.Of 15 peer CEOs

CEO pay, last three years

  • $6,583,672FY2023

CEO total pay was $6,583,672 in fiscal 2023; the brief holds no earlier figure for this CEO.

FY2023: salary $925,000 · bonus $0 · stock awards $3,850,216 · option awards $1,650,019

Executives and directors

Frequently asked questions

Who was the highest-paid executive at Catalent, Inc. in fiscal 2023?
As disclosed, Alessandro Maselli (President and Chief Executive Officer) was the highest-paid executive at Catalent, Inc. in fiscal 2023, with total compensation of $6,583,672.
How does Catalent, Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, Alessandro Maselli's total compensation ranked at the 1st percentile of Catalent, Inc.'s disclosed peer group.
How did shareholders vote on Catalent, Inc.'s executive compensation?
As disclosed, 97.01% of shareholders supported Catalent, Inc.'s executive compensation in the latest say-on-pay vote.
How much does Catalent, Inc. spend in total on board compensation for fiscal 2023?
As disclosed, Catalent, Inc. reported total board compensation of $4,688,322 for fiscal 2023.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

Full detail

Every table from the filing. Open any section.

Summary compensation table
Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Alessandro Maselli$925,000$0$3,850,216$1,650,019$0$0$158,437$6,583,672
President and Chief Executive Officer
John Chiminski700,00004,000,069000107,6984,807,767
Former Executive Chair
Manja Boerman511,38702,455,217195,02200818,2623,979,888
Former President, Division Head for Biomodalities
Aristippos Gennadios600,00002,700,277300,017135,000064,2633,799,557
Group President, Pharma and Consumer Health
Thomas Castellano443,6540875,098375,003001,036,2282,729,983
Former Senior Vice President and Chief Financial Officer
Steven Fasman625,00001,050,221450,025135,000050,0532,310,299
Former Executive Vice President & Chief Administrative Officer
Ricky Hopson380,0000245,150105,032139,5000102,625972,307
President, Division Head for Clinical Development & Supply and Former Interim Chief Financial Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2023 totalFY2022 totalFY2021 totalΔ FY2022→2023
Alessandro Maselli$6,583,672$3,234,030$5,062,439↑ +3,349,642
John Chiminski4,807,76712,407,51712,581,139↓ −7,599,750
Manja Boerman3,979,888———
Aristippos Gennadios3,799,5572,125,504—↑ +1,674,053
Thomas Castellano2,729,9831,671,0671,778,546↑ +1,058,916
Steven Fasman2,310,2992,799,5232,317,605↓ −489,224
Ricky Hopson972,307———

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

Incentive-plan design — the Compensation Discussion & Analysis

Our executive compensation program is intended to attract, motivate, retain, and reward our leadership in a manner that will align their interests with those of our shareholders on an annual and long-term basis and promote sustainable shareholder value creation. We seek to maintain a competitive program that ties a significant portion of executive pay to our financial and stock price performance.

CEO STI target (% of salary)—
CEO LTI target (% of salary)—
Independent consultantFrederic W. Cook & Co., Inc.
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
Equity grants and outstanding awards

Grants of plan-based awards — fiscal year 2023

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Manja BoermanPSU2022-07-269,29218,583—37,166$2,000,088
Thomas CastellanoPSU2022-07-261,5793,158—4,737312,516
Thomas CastellanoPSU2022-07-261,4522,904—5,808312,558
John ChiminskiRSU2022-07-26——37,165—4,000,069
Steven FasmanOPTION2022-07-26——12,117—450,025
Aristippos GennadiosOPTION2022-07-26——8,078—300,017
Aristippos GennadiosPSU2022-07-261,1622,323—4,646250,024
Ricky HopsonRSU2022-07-26——651—70,067
Ricky HopsonPSU2022-07-26443885—1,32887,580
Steven FasmanRSU2022-07-26——2,788—300,072
Manja BoermanPSU2022-07-267551,510—3,020162,521
Manja BoermanRSU2022-07-26——1,208—130,017
Manja BoermanPSU2022-07-268221,643—2,465162,591
Thomas CastellanoRSU2022-07-26——2,323—250,024
Steven FasmanPSU2022-07-261,7433,485—6,970375,091
Steven FasmanPSU2022-07-261,8953,790—5,685375,058
Aristippos GennadiosPSU2022-07-261,2642,527—3,791250,072
Aristippos GennadiosRSU2022-07-26——1,859—200,084
Aristippos GennadiosRSU2022-07-01——18,689—2,000,097
Ricky HopsonPSU2022-07-26407813—1,62687,503
Alessandro MaselliRSU2022-07-26——10,221—1,100,086
Alessandro MaselliPSU2022-07-266,94813,895—20,8431,375,049
Alessandro MaselliPSU2022-07-266,38812,776—25,5521,375,081
Ricky HopsonOPTION2022-07-26——2,828—105,032
Thomas CastellanoOPTION2022-07-26——10,097—375,003
Manja BoermanOPTION2022-07-26——5,251—195,022
Alessandro MaselliOPTION2022-07-26——44,427—1,650,019

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Manja Boerman$130,017$2,325,200$195,02287.7%
Thomas Castellano250,024625,074375,00350.0%
John Chiminski4,000,069000.0%
Steven Fasman300,072750,149450,02550.0%
Aristippos Gennadios2,200,181500,096300,01716.7%
Ricky Hopson70,067175,083105,03250.0%
Alessandro Maselli1,100,0862,750,1301,650,01950.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

Outstanding equity awards at fiscal year-end 2023

ExecutiveAwardExercisableShares unvestedExercise priceMarket value unvested
Alessandro MaselliOption—44,427107.63—
Alessandro MaselliRSU—10,221—443,183
Alessandro MaselliPSU—6,388—276,984
Alessandro MaselliPSU—6,948—301,265
Alessandro MaselliOption3,89211,676113—
Alessandro MaselliRSU—3,009—130,470
Alessandro MaselliPSU—1,881—81,560
Alessandro MaselliPSU—1,949—84,509
Alessandro MaselliOption7,6967,69988.1—
Alessandro MaselliRSU—2,838—123,056
Alessandro MaselliRSU—3,761—163,077
Alessandro MaselliOption10,2993,43654.94—
Alessandro MaselliOption10,523—43.88—
Alessandro MaselliOption10,375—36.02—
Alessandro MaselliOption11,093—23.89—
Aristippos GennadiosOption—8,078107.63—
Aristippos GennadiosRSU—1,859—80,606
Aristippos GennadiosPSU—1,162—50,384
Aristippos GennadiosPSU—1,264—54,807
Aristippos GennadiosRSU—18,689—810,355
Aristippos GennadiosRSU—4,017—174,177
Aristippos GennadiosOption1,1443,435113—
Aristippos GennadiosRSU—885—38,374
Aristippos GennadiosPSU—554—24,021
Aristippos GennadiosPSU—574—24,889
Aristippos GennadiosOption3,0783,08088.1—
Aristippos GennadiosRSU—1,136—49,257
Aristippos GennadiosRSU—1,505—65,257
Aristippos GennadiosOption6,6212,20954.94—
Aristippos GennadiosOption10,523—43.88—
Aristippos GennadiosOption3,243—36.02—
John ChiminskiRSU—37,165—1,611,474
John ChiminskiOption21,29163,874113—
John ChiminskiRSU—16,461—713,749
John ChiminskiPSU—6,859—297,406
John ChiminskiPSU—7,107—308,160
John ChiminskiOption55,88055,88288.1—
John ChiminskiRSU—20,602—893,303
John ChiminskiRSU—27,298—1,183,641
John ChiminskiOption64,74832,37554.94—
John ChiminskiOption34,638—43.88—
Manja BoermanOption—5,251107.63—
Manja BoermanRSU—1,208—52,379
Manja BoermanPSU—755—32,737
Manja BoermanPSU—822—35,642
Manja BoermanPSU—18,583—805,759
Manja BoermanRSU—4,017—174,177
Manja BoermanOption1,1443,435113—
Manja BoermanRSU—885—38,374
Manja BoermanPSU—554—24,021
Manja BoermanPSU—574—24,889
Manja BoermanOption3,0783,08088.1—
Manja BoermanRSU—1,136—49,257
Manja BoermanRSU—1,505—65,257
Manja BoermanOption6,3332,11251.43—
Ricky HopsonOption—2,828107.63—
Ricky HopsonRSU—651—28,227
Ricky HopsonPSU—407—17,648
Ricky HopsonPSU—443—19,208
Ricky HopsonOption6411,924113—
Ricky HopsonRSU—496—21,507
Ricky HopsonPSU—310—13,442
Ricky HopsonPSU—321—13,919
Ricky HopsonRSU—3,432—148,812
Ricky HopsonOption1,5261,52988.1—
Ricky HopsonRSU—563—24,412
Ricky HopsonRSU—747—32,390
Ricky HopsonOption2,4321,21854.94—
Ricky HopsonOption2,622—43.88—
Ricky HopsonOption1,550—36.02—
Steven FasmanOption—12,117107.63—
Steven FasmanRSU—2,788—120,888
Steven FasmanPSU—1,743—75,576
Steven FasmanPSU—1,895—82,167
Steven FasmanRSU—4,017—174,177
Steven FasmanOption2,2896,869113—
Steven FasmanRSU—1,770—76,747
Steven FasmanPSU—1,107—48,000
Steven FasmanPSU—1,147—49,734
Steven FasmanOption2,1554,31188.1—
Director compensation
DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
J. Martin CarrollIndependent · Lead Independent Director · Compensation and Leadership · Nominating and Corporate Governance · Quality and Regulatory Compliance (Chair)$151,401$274,954———$426,355
John J. GreischNot independent · Board Chair · Strategic and Operational Review (Chair)125,907274,954———400,861
Jack StahlIndependent · Audit (Chair)120,151274,954———395,105
Gregory T. LucierIndependent · Audit · Compensation and Leadership (Chair)112,651274,954———387,605
Rosemary A. CraneIndependent110,000274,954———384,954
Donald E. Morel JrIndependent · Quality and Regulatory Compliance110,000274,954———384,954
Rolf ClassonIndependent · Audit · Compensation and Leadership · Nominating and Corporate Governance (Chair)110,000274,954———384,954
Christa KreuzburgIndependent100,151274,954———375,105
Michael J. BarberIndependent · Compensation and Leadership · Nominating and Corporate Governance100,000274,954———374,954
Madhavan BalachandranIndependent100,000274,954———374,954
Karen FlynnNot independent · Not standing for re-election60,440296,818———357,258
Peter ZippeliusNot independent · Not standing for re-election · Departed during FY58,611274,954———333,565
John ChiminskiEmployee director · Departed during FY000—107,698107,698
Stephanie OkeyIndependent · Compensation and Leadership · Nominating and Corporate Governance · Newly elected—————0
Michelle R. RyanIndependent · Audit · Newly elected—————0
Alessandro MaselliEmployee director—————0
Steven K. BargIndependent · Quality and Regulatory Compliance · Newly elected—————0
Frank A. D'AmelioNewly elected——————

Board fee structure and ownership guideline

Annual cash retainer$100,000
Annual equity retainer$275,000
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)25,000 / 12,500 / 10,000
Stock ownership guideline$5

Total cost of the board

ComponentFY2023
Cash retainers and fees$1,259,312
Equity awards (grant-date value)$3,321,312
All other compensation$107,698
Total cost of the board$4,688,322

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

Peer group, and who names Catalent as a peer

Companies that benchmark against CLT

1 company names CLT as a compensation peer

Each company listed discloses CLT in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named CLT in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

Disclosed peer group — fiscal year 2023

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

Peer reciprocity

The companies Catalent, Inc. names as compensation peers that name it back in their own disclosed peer groups.

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Incyte Corporation2025William Meury$647,260$27,509,657$2,573,998$1,300,000$32,085,952
2Biogen Inc.2025Christopher Viehbacher1,727,88518,368,87503,190,87523,646,004
3Boston Scientific Corporation2025Michael Mahoney1,442,60313,608,0563,749,9804,002,00123,532,050
4Vertex Pharmaceuticals Incorporated2025Reshma Kewalramani1,600,00015,002,27004,118,64021,144,261
5Horizon Pharma plc2022Timothy Walbert1,292,72716,601,3050020,103,869
6Align Technology, Inc.2025Joseph Hogan1,400,00016,556,87201,220,10019,193,988
7Jazz Pharmaceuticals plc2025Renee Gala1,003,26916,138,43301,980,00019,151,558
8The Cooper Companies, Inc.2025Albert White III1,170,7696,642,9186,643,0501,525,95116,051,141
9Hologic, Inc.2025Stephen MacMillan1,255,0709,608,8923,149,9991,436,38415,931,655
10Agilent Technologies, Inc.2025Padraig McDonnell1,141,3458,169,8502,017,7591,436,80912,827,236
11Steris plc2026Daniel Carestio1,095,7074,333,9514,334,2511,725,00711,508,522
12Perrigo plc2025Patrick Lockwood-Taylor1,223,3336,990,5640687,2509,042,603
13Bio-Rad Laboratories, Inc.2025Norman Schwartz1,089,8774,856,5741,458,975562,0887,995,841
14West Pharmaceutical Services, Inc.2025Eric Green1,177,2903,327,0481,108,9611,471,6137,190,876
15Mettler-Toledo International Inc.2025Patrick Kaltenbach1,145,9993,267,8081,635,033462,9846,741,212
16Catalent, Inc.2023Alessandro Maselli925,0003,850,2161,650,01906,583,672

Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Catalent, Inc.100%PSU 50 · Option 30 · RSU 20not disclosedFrederic W. Cook & Co., Inc.
Agilent Technologies, Inc.86%PSU 60 · Option 20 · RSU 20NoSemler Brossy
Align Technology, Inc.58.1%MSU 70 · RSU 30Yes — Relative Total Stockholder Return (TSR) vs. Nasdaq Composite IndexCompensia, Inc.
Bio-Rad Laboratories, Inc.70.8%not disclosednot disclosedCompensia, Inc.
Biogen Inc.127%PSU 60 · RSU 40YesPay Governance
Boston Scientific Corporation173%PSU 50 · RSU 25 · Options 25NoSemler Brossy Consulting Group, LLC
Hologic, Inc.not disclosedPSU 50 · RSU 25 · Option 25not disclosedPearl Meyer & Partners, LLC
Horizon Pharma plc100%RSU 50 · PSU 50Yes — Relative TSRAon
Incyte Corporation138.6%PSU 60 · RSU 20 · Option 20Yes — relative total shareholder return (TSR)Aon
Jazz Pharmaceuticals plc150%RSU 50 · PSU 50Yes — Relative TSRAon
Mettler-Toledo International Inc.not disclosednot disclosedYes — Relative Total Shareholder Return (rTSR)Pearl Meyer & Partners
Perrigo plc44.3%PSU 70 · RSU 30Yes — Relative TSR (rTSR)Frederic W. Cook & Company, Inc.
Steris plc125.1%Option 50 · Restricted Stock 50not disclosedFrederic W. Cook & Co., Inc.
The Cooper Companies, Inc.100.9%Options 50 · PSU 50NoCompensia
Vertex Pharmaceuticals Incorporatednot disclosedPSU 55 · RSU 45NoPearl Meyer
West Pharmaceutical Services, Inc.100%PSU 50 · RSU 25 · Options 25NoPay Governance

Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.

Say-on-pay history and pay ratio
Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20242024-01-25152,656,9954,216,702485,00897.01%Passed
20222022-10-27156,798,2637,319,365336,04095.34%Passed
20212021-10-28156,030,4165,100,57730,35596.83%Passed
20202020-10-29159,906,9073,335,249150,49297.87%Passed
20192019-10-30149,390,9671,941,030166,19098.61%Passed
20182018-10-31129,379,8634,072,327165,60596.83%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.

Say-on-pay — history, company’s computation

Meeting yearMeeting dateApproval — company’s computation
20242024-01-2597.01%a
20222022-10-2795.34%b
20212021-10-2896.83%c

a. Approved under the standard stated in the filing — “Majority in voting power of the shares present in person or represented by proxy and entitled to vote on the subject matter. | Abstentions: Abstentions will have the effect of a vote against. Broker non-votes will have no effect on the outcome.”.

b. Approved under the standard stated in the filing — “Majority in voting power of the shares present in person or represented by proxy and entitled to vote on the matter. | Abstentions: Abstentions will have the effect of a vote against. Broker non-votes will have no effect on the outcome.”.

c. Voting standard not stated in the filing.

Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

Insider trades since the proxy

Every insider equity transaction reported on Form 4 after the 2023 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Michael HatzfeldChief Accounting Officer2024-01-16A6,071$0$0CommonForm 4 ↗
Michael HatzfeldChief Accounting Officer2024-01-16A3,98100Derivative, Class A CommonForm 4 ↗
Michael HatzfeldChief Accounting Officer2024-01-16A1,83700CommonForm 4 ↗
Christa KreuzburgDirector2024-01-25D5235026,364CommonForm 4 ↗
Scott GuntherSVP, Quality & Reg. Affairs2024-03-15D3875621,749CommonForm 4 ↗
Ricky HopsonPres. BioProduct Delivery, CoS2024-06-04D1,4015476,023CommonForm 4 ↗
Matti MasanovichSVP, Chief Financial Officer2024-07-08D2,99357169,823CommonForm 4 ↗
Matti MasanovichSVP, Chief Financial Officer2024-07-26A42,60400CommonForm 4 ↗
Scott GuntherSVP, Quality & Reg. Affairs2024-07-26A11,07800CommonForm 4 ↗
Aristippos GennadiosGroup Pres. Pharma & Consumer2024-07-26A18,74600CommonForm 4 ↗
Lisa EvoliSVP, Chief HR Officer2024-07-26A15,33800CommonForm 4 ↗
Michael HatzfeldChief Accounting Officer2024-07-26A5,62400CommonForm 4 ↗
Joseph Anthony FerraroSVP, General Counsel, CCO2024-07-26A17,04200CommonForm 4 ↗
Alessandro MaselliDirector2024-07-26A98,67100CommonForm 4 ↗
John J. GreischDirector2024-07-26A63,73600CommonForm 4 ↗
Ricky HopsonPres. BioProduct Delivery, CoS2024-07-26A10,22500CommonForm 4 ↗
David McErlaneGroup President, Biologics2024-07-26A18,74600CommonForm 4 ↗
Alessandro MaselliDirector2024-07-29D9,08859534,011CommonForm 4 ↗
Ricky HopsonPres. BioProduct Delivery, CoS2024-07-29D2065912,086CommonForm 4 ↗
Scott GuntherSVP, Quality & Reg. Affairs2024-07-29D2835916,609CommonForm 4 ↗
Aristippos GennadiosGroup Pres. Pharma & Consumer2024-07-29D3495920,486CommonForm 4 ↗
Joseph Anthony FerraroSVP, General Counsel, CCO2024-08-02D6086036,225CommonForm 4 ↗
Ricky HopsonPres. BioProduct Delivery, CoS2024-08-02D6626039,429CommonForm 4 ↗
Scott GuntherSVP, Quality & Reg. Affairs2024-08-02D6666039,660CommonForm 4 ↗
Lisa EvoliSVP, Chief HR Officer2024-08-02D3,85960230,267CommonForm 4 ↗
Aristippos GennadiosGroup Pres. Pharma & Consumer2024-08-02D1,1696069,614CommonForm 4 ↗
David McErlaneGroup President, Biologics2024-09-26D1,99460119,580CommonForm 4 ↗
Joseph Anthony FerraroSVP, General Counsel, CCO2024-10-18D3206019,190CommonForm 4 ↗
Michael J. BarberDirector2024-10-30A4,66300CommonForm 4 ↗
Gregory T. LucierDirector2024-10-30A4,66300CommonForm 4 ↗
Michelle R. RyanDirector2024-10-30A4,66300CommonForm 4 ↗
Jack StahlDirector2024-10-30A4,66300CommonForm 4 ↗
Steven K. BargDirector2024-10-30A4,66300CommonForm 4 ↗
Stephanie OkeyDirector2024-10-30A4,66300CommonForm 4 ↗
Frank A. DamelioDirector2024-10-30A4,66300CommonForm 4 ↗
Donald E. Morel JrDirector2024-10-30A4,66300CommonForm 4 ↗
J. Martin CarrollDirector2024-10-30A4,66300CommonForm 4 ↗
Rolf ClassonDirector2024-10-30A4,66300CommonForm 4 ↗
Michelle R. RyanDirector2024-11-11D2,80060167,160CommonForm 4 ↗
Rolf ClassonDirector2024-12-18D47,984——CommonForm 4 ↗
Gregory T. LucierDirector2024-12-18D36,914——CommonForm 4 ↗
Alessandro MaselliDirector2024-12-18D15,568——Derivative, Class A CommonForm 4 ↗
Alessandro MaselliDirector2024-12-18D10,523——Derivative, Class A CommonForm 4 ↗
David McErlaneGroup President, Biologics2024-12-18D36,304——CommonForm 4 ↗
Stephanie OkeyDirector2024-12-18D12,635——CommonForm 4 ↗
Joseph Anthony FerraroSVP, General Counsel, CCO2024-12-18D23,967——CommonForm 4 ↗
Ricky HopsonPres. BioProduct Delivery, CoS2024-12-18D2,565——Derivative, Class A CommonForm 4 ↗
Ricky HopsonPres. BioProduct Delivery, CoS2024-12-18D3,650——Derivative, Class A CommonForm 4 ↗
Ricky HopsonPres. BioProduct Delivery, CoS2024-12-18D2,622——Derivative, Class A CommonForm 4 ↗
Ricky HopsonPres. BioProduct Delivery, CoS2024-12-18D1,550——Derivative, Class A CommonForm 4 ↗
Michael J. BarberDirector2024-12-18D18,052——CommonForm 4 ↗
Michelle R. RyanDirector2024-12-18D10,835——CommonForm 4 ↗
Ricky HopsonPres. BioProduct Delivery, CoS2024-12-18D10,722——CommonForm 4 ↗
Ricky HopsonPres. BioProduct Delivery, CoS2024-12-18D29,974——CommonForm 4 ↗
Aristippos GennadiosGroup Pres. Pharma & Consumer2024-12-18D21,562——CommonForm 4 ↗
Alessandro MaselliDirector2024-12-18D15,395——Derivative, Class A CommonForm 4 ↗
Jack StahlDirector2024-12-18D47,984——CommonForm 4 ↗
John J. GreischDirector2024-12-18D33,530——CommonForm 4 ↗
Michael HatzfeldChief Accounting Officer2024-12-18A3,14400CommonForm 4 ↗
David McErlaneGroup President, Biologics2024-12-18A11,42600CommonForm 4 ↗
Michael HatzfeldChief Accounting Officer2024-12-18D3,144——CommonForm 4 ↗
Michael HatzfeldChief Accounting Officer2024-12-18D13,532——CommonForm 4 ↗
Scott GuntherSVP, Quality & Reg. Affairs2024-12-18A12,93800CommonForm 4 ↗
Scott GuntherSVP, Quality & Reg. Affairs2024-12-18D12,938——CommonForm 4 ↗
Joseph Anthony FerraroSVP, General Counsel, CCO2024-12-18A14,26500CommonForm 4 ↗
Joseph Anthony FerraroSVP, General Counsel, CCO2024-12-18D14,265——CommonForm 4 ↗
Donald E. Morel JrDirector2024-12-18D70,118——CommonForm 4 ↗
Frank A. DamelioDirector2024-12-18D12,635——CommonForm 4 ↗
J. Martin CarrollDirector2024-12-18D32,734——CommonForm 4 ↗
Steven K. BargDirector2024-12-18D12,374——CommonForm 4 ↗
Alessandro MaselliDirector2024-12-18A113,22400CommonForm 4 ↗
David McErlaneGroup President, Biologics2024-12-18D14,740——Derivative, Class A CommonForm 4 ↗
Alessandro MaselliDirector2024-12-18D103,360——Derivative, Class A CommonForm 4 ↗
Alessandro MaselliDirector2024-12-18D44,427——Derivative, Class A CommonForm 4 ↗
Alessandro MaselliDirector2024-12-18D13,735——Derivative, Class A CommonForm 4 ↗
Alessandro MaselliDirector2024-12-18D10,375——Derivative, Class A CommonForm 4 ↗
Alessandro MaselliDirector2024-12-18D11,093——Derivative, Class A CommonForm 4 ↗
Alessandro MaselliDirector2024-12-18D113,224——CommonForm 4 ↗
Ricky HopsonPres. BioProduct Delivery, CoS2024-12-18A10,72200CommonForm 4 ↗
Ricky HopsonPres. BioProduct Delivery, CoS2024-12-18D10,669——Derivative, Class A CommonForm 4 ↗
Ricky HopsonPres. BioProduct Delivery, CoS2024-12-18D2,828——Derivative, Class A CommonForm 4 ↗
Ricky HopsonPres. BioProduct Delivery, CoS2024-12-18D3,055——Derivative, Class A CommonForm 4 ↗
Matti MasanovichSVP, Chief Financial Officer2024-12-18A71,69100CommonForm 4 ↗
Scott GuntherSVP, Quality & Reg. Affairs2024-12-18D39,635——CommonForm 4 ↗
Matti MasanovichSVP, Chief Financial Officer2024-12-18D81,082——Derivative, Class A CommonForm 4 ↗
Matti MasanovichSVP, Chief Financial Officer2024-12-18D71,691——CommonForm 4 ↗
Matti MasanovichSVP, Chief Financial Officer2024-12-18D76,475——CommonForm 4 ↗
John J. GreischDirector2024-12-18A33,53000CommonForm 4 ↗
John J. GreischDirector2024-12-18D127,096——Derivative, Class A CommonForm 4 ↗
John J. GreischDirector2024-12-18D34,000——CommonForm 4 ↗
Lisa EvoliSVP, Chief HR Officer2024-12-18A12,03200CommonForm 4 ↗
Lisa EvoliSVP, Chief HR Officer2024-12-18D14,225——Derivative, Class A CommonForm 4 ↗
Lisa EvoliSVP, Chief HR Officer2024-12-18D12,032——CommonForm 4 ↗
Lisa EvoliSVP, Chief HR Officer2024-12-18D39,366——CommonForm 4 ↗
Aristippos GennadiosGroup Pres. Pharma & Consumer2024-12-18A21,56200CommonForm 4 ↗
John J. GreischDirector2024-12-18D79,932——CommonForm 4 ↗
Aristippos GennadiosGroup Pres. Pharma & Consumer2024-12-18D113,724——CommonForm 4 ↗
Alessandro MaselliDirector2024-12-18D177,521——CommonForm 4 ↗
David McErlaneGroup President, Biologics2024-12-18D11,426——CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

Sources (174 citations)

Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.

  • Section 01, Alessandro Maselli. DEF 14A, filed 2023-12-15. Section “Fiscal 2023 Summary Compensation Table”. As printed: 6,583,672. View filing ↗
  • Section 01, John Chiminski. DEF 14A, filed 2023-12-15. Section “Fiscal 2023 Summary Compensation Table”. As printed: 4,807,767. View filing ↗
  • Section 01, Manja Boerman. DEF 14A, filed 2023-12-15. Section “Fiscal 2023 Summary Compensation Table”. As printed: 3,979,888. View filing ↗
  • Section 01, Aristippos Gennadios. DEF 14A, filed 2023-12-15. Section “Fiscal 2023 Summary Compensation Table”. As printed: 3,799,557. View filing ↗
  • Section 01, Thomas Castellano. DEF 14A, filed 2023-12-15. Section “Fiscal 2023 Summary Compensation Table”. As printed: 2,729,983. View filing ↗
  • Section 01, Steven Fasman. DEF 14A, filed 2023-12-15. Section “Fiscal 2023 Summary Compensation Table”. As printed: 2,310,299. View filing ↗
  • Section 01, Ricky Hopson. DEF 14A, filed 2023-12-15. Section “Fiscal 2023 Summary Compensation Table”. As printed: 972,307. View filing ↗
  • Section 03, Manja Boerman PSU. DEF 14A, filed 2023-12-15. Section “Fiscal 2023 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
  • Section 03, Thomas Castellano PSU. DEF 14A, filed 2023-12-15. Section “Fiscal 2023 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
  • Section 03, Thomas Castellano PSU. DEF 14A, filed 2023-12-15. Section “Fiscal 2023 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
  • Section 03, John Chiminski RSU. DEF 14A, filed 2023-12-15. Section “Fiscal 2023 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
  • Section 03, Steven Fasman OPTION. DEF 14A, filed 2023-12-15. Section “Fiscal 2023 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
  • Section 03, Aristippos Gennadios OPTION. DEF 14A, filed 2023-12-15. Section “Fiscal 2023 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
  • Section 03, Aristippos Gennadios PSU. DEF 14A, filed 2023-12-15. Section “Fiscal 2023 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
  • Section 03, Ricky Hopson RSU. DEF 14A, filed 2023-12-15. Section “Fiscal 2023 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
  • Section 03, Ricky Hopson PSU. DEF 14A, filed 2023-12-15. Section “Fiscal 2023 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
  • Section 03, Steven Fasman RSU. DEF 14A, filed 2023-12-15. Section “Fiscal 2023 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
  • Section 03, Manja Boerman PSU. DEF 14A, filed 2023-12-15. Section “Fiscal 2023 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
  • Section 03, Manja Boerman RSU. DEF 14A, filed 2023-12-15. Section “Fiscal 2023 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
  • Section 03, Manja Boerman PSU. DEF 14A, filed 2023-12-15. Section “Fiscal 2023 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
  • Section 03, Thomas Castellano RSU. DEF 14A, filed 2023-12-15. Section “Fiscal 2023 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
  • Section 03, Steven Fasman PSU. DEF 14A, filed 2023-12-15. Section “Fiscal 2023 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
  • Section 03, Steven Fasman PSU. DEF 14A, filed 2023-12-15. Section “Fiscal 2023 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
  • Section 03, Aristippos Gennadios PSU. DEF 14A, filed 2023-12-15. Section “Fiscal 2023 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
  • Section 03, Aristippos Gennadios RSU. DEF 14A, filed 2023-12-15. Section “Fiscal 2023 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
  • Section 03, Aristippos Gennadios RSU. DEF 14A, filed 2023-12-15. Section “Fiscal 2023 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
  • Section 03, Ricky Hopson PSU. DEF 14A, filed 2023-12-15. Section “Fiscal 2023 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
  • Section 03, Alessandro Maselli RSU. DEF 14A, filed 2023-12-15. Section “Fiscal 2023 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
  • Section 03, Alessandro Maselli PSU. DEF 14A, filed 2023-12-15. Section “Fiscal 2023 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
  • Section 03, Alessandro Maselli PSU. DEF 14A, filed 2023-12-15. Section “Fiscal 2023 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
  • Section 03, Ricky Hopson OPTION. DEF 14A, filed 2023-12-15. Section “Fiscal 2023 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
  • Section 03, Thomas Castellano OPTION. DEF 14A, filed 2023-12-15. Section “Fiscal 2023 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
  • Section 03, Manja Boerman OPTION. DEF 14A, filed 2023-12-15. Section “Fiscal 2023 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
  • Section 03, Alessandro Maselli OPTION. DEF 14A, filed 2023-12-15. Section “Fiscal 2023 Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
  • Section 08, J. Martin Carroll. DEF 14A, filed 2023-12-15. Section “Director Compensation”. As printed: 426,355. View filing ↗
  • Section 08, John J. Greisch. DEF 14A, filed 2023-12-15. Section “Director Compensation”. As printed: 400,861. View filing ↗
  • Section 08, Jack Stahl. DEF 14A, filed 2023-12-15. Section “Director Compensation”. As printed: 395,105. View filing ↗
  • Section 08, Gregory T. Lucier. DEF 14A, filed 2023-12-15. Section “Director Compensation”. As printed: 387,605. View filing ↗
  • Section 08, Rosemary A. Crane. DEF 14A, filed 2023-12-15. Section “Director Compensation”. As printed: 384,954. View filing ↗
  • Section 08, Donald E. Morel Jr. DEF 14A, filed 2023-12-15. Section “Director Compensation”. As printed: 384,954. View filing ↗
  • Section 08, Rolf Classon. DEF 14A, filed 2023-12-15. Section “Director Compensation”. As printed: 384,954. View filing ↗
  • Section 08, Christa Kreuzburg. DEF 14A, filed 2023-12-15. Section “Director Compensation”. As printed: 375,105. View filing ↗
  • Section 08, Michael J. Barber. DEF 14A, filed 2023-12-15. Section “Director Compensation”. As printed: 374,954. View filing ↗
  • Section 08, Madhavan Balachandran. DEF 14A, filed 2023-12-15. Section “Director Compensation”. As printed: 374,954. View filing ↗
  • Section 08, Karen Flynn. DEF 14A, filed 2023-12-15. Section “Director Compensation”. As printed: 357,258. View filing ↗
  • Section 08, Peter Zippelius. DEF 14A, filed 2023-12-15. Section “Director Compensation”. As printed: 333,565. View filing ↗
  • Section 08, John Chiminski. DEF 14A, filed 2023-12-15. Section “Director Compensation”. As printed: 107,698. View filing ↗
  • Section 08, Stephanie Okey. DEF 14A, filed 2023-12-15. Section “Director Compensation”. As printed: 0. View filing ↗
  • Section 08, Michelle R. Ryan. DEF 14A, filed 2023-12-15. Section “Director Compensation”. As printed: 0. View filing ↗
  • Section 08, Alessandro Maselli. DEF 14A, filed 2023-12-15. Section “Director Compensation”. As printed: 0. View filing ↗
  • Section 08, Steven K. Barg. DEF 14A, filed 2023-12-15. Section “Director Compensation”. As printed: 0. View filing ↗
  • Section 08, Frank A. D'Amelio. DEF 14A, filed 2023-12-15. Section “Director Compensation”. As printed: —. View filing ↗
  • Section 02, Michael Hatzfeld 2024-01-16. Form 4, filed 2024-01-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Michael Hatzfeld 2024-01-16. Form 4, filed 2024-01-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Michael Hatzfeld 2024-01-16. Form 4, filed 2024-01-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Christa Kreuzburg 2024-01-25. Form 4, filed 2024-01-29. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Scott Gunther 2024-03-15. Form 4, filed 2024-03-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ricky Hopson 2024-06-04. Form 4, filed 2024-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Matti Masanovich 2024-07-08. Form 4, filed 2024-07-10. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Matti Masanovich 2024-07-26. Form 4, filed 2024-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Scott Gunther 2024-07-26. Form 4, filed 2024-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Aristippos Gennadios 2024-07-26. Form 4, filed 2024-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Lisa Evoli 2024-07-26. Form 4, filed 2024-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Michael Hatzfeld 2024-07-26. Form 4, filed 2024-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Joseph Anthony Ferraro 2024-07-26. Form 4, filed 2024-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Alessandro Maselli 2024-07-26. Form 4, filed 2024-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, John J. Greisch 2024-07-26. Form 4, filed 2024-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ricky Hopson 2024-07-26. Form 4, filed 2024-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, David McErlane 2024-07-26. Form 4, filed 2024-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Alessandro Maselli 2024-07-29. Form 4, filed 2024-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ricky Hopson 2024-07-29. Form 4, filed 2024-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Scott Gunther 2024-07-29. Form 4, filed 2024-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Aristippos Gennadios 2024-07-29. Form 4, filed 2024-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Joseph Anthony Ferraro 2024-08-02. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ricky Hopson 2024-08-02. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Scott Gunther 2024-08-02. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Lisa Evoli 2024-08-02. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Aristippos Gennadios 2024-08-02. Form 4, filed 2024-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, David McErlane 2024-09-26. Form 4, filed 2024-09-27. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Joseph Anthony Ferraro 2024-10-18. Form 4, filed 2024-10-21. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Michael J. Barber 2024-10-30. Form 4, filed 2024-11-01. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Gregory T. Lucier 2024-10-30. Form 4, filed 2024-11-01. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Michelle R. Ryan 2024-10-30. Form 4, filed 2024-11-01. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jack Stahl 2024-10-30. Form 4, filed 2024-11-01. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Steven K. Barg 2024-10-30. Form 4, filed 2024-11-01. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Stephanie Okey 2024-10-30. Form 4, filed 2024-11-01. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Frank A. Damelio 2024-10-30. Form 4, filed 2024-11-01. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Donald E. Morel Jr 2024-10-30. Form 4, filed 2024-11-01. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, J. Martin Carroll 2024-10-30. Form 4, filed 2024-11-01. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Rolf Classon 2024-10-30. Form 4, filed 2024-11-01. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Michelle R. Ryan 2024-11-11. Form 4, filed 2024-11-14. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Rolf Classon 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Gregory T. Lucier 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Alessandro Maselli 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Alessandro Maselli 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, David McErlane 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Stephanie Okey 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Joseph Anthony Ferraro 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ricky Hopson 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ricky Hopson 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ricky Hopson 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ricky Hopson 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Michael J. Barber 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Michelle R. Ryan 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ricky Hopson 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ricky Hopson 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Aristippos Gennadios 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Alessandro Maselli 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jack Stahl 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, John J. Greisch 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Michael Hatzfeld 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, David McErlane 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Michael Hatzfeld 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Michael Hatzfeld 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Scott Gunther 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Scott Gunther 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Joseph Anthony Ferraro 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Joseph Anthony Ferraro 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Donald E. Morel Jr 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Frank A. Damelio 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, J. Martin Carroll 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Steven K. Barg 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Alessandro Maselli 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, David McErlane 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Alessandro Maselli 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Alessandro Maselli 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Alessandro Maselli 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Alessandro Maselli 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Alessandro Maselli 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Alessandro Maselli 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ricky Hopson 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ricky Hopson 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ricky Hopson 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ricky Hopson 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Matti Masanovich 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Scott Gunther 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Matti Masanovich 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Matti Masanovich 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Matti Masanovich 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, John J. Greisch 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, John J. Greisch 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, John J. Greisch 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Lisa Evoli 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Lisa Evoli 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Lisa Evoli 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Lisa Evoli 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Aristippos Gennadios 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, John J. Greisch 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Aristippos Gennadios 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Alessandro Maselli 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, David McErlane 2024-12-18. Form 4, filed 2024-12-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 06, 2024 vote. Form 8-K, filed 2024-01-26. Item 5.07 · say-on-pay result. As reported: 97.01% (votes for as printed: 152,656,995). View filing ↗
  • Section 06, 2022 vote. Form 8-K, filed 2022-11-01. Item 5.07 · say-on-pay result. As reported: 95.34% (votes for as printed: 156,798,263). View filing ↗
  • Section 06, 2021 vote. Form 8-K, filed 2021-11-02. Item 5.07 · say-on-pay result. As reported: 96.83% (votes for as printed: 156,030,416). View filing ↗
  • Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
  • Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
  • Section 09b board cost (computed). Computed. Cash 1,259,312 + equity 3,321,312 + all other 107,698 = 4,688,322, summed across the director compensation table rows.
  • Incyte Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Incyte Corporation's own proxy. As printed: 32,085,952. View filing ↗
  • Biogen Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Biogen Inc.'s own proxy. As printed: 23,646,004. View filing ↗
  • Boston Scientific Corporation, Section 10b CEO total. DEF 14A, filed 2026-03-18. CEO total compensation as printed in Boston Scientific Corporation's own proxy. As printed: 23,532,050. View filing ↗
  • Vertex Pharmaceuticals Incorporated, Section 10b CEO total. DEF 14A, filed 2026-04-02. CEO total compensation as printed in Vertex Pharmaceuticals Incorporated's own proxy. As printed: 21,144,261. View filing ↗
  • Horizon Pharma plc, Section 10b CEO total. DEF 14A, filed 2023-06-30. CEO total compensation as printed in Horizon Pharma plc's own proxy. As printed: 20,103,869. View filing ↗
  • Align Technology, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Align Technology, Inc.'s own proxy. As printed: 19,193,988. View filing ↗
  • Jazz Pharmaceuticals plc, Section 10b CEO total. DEF 14A, filed 2026-06-08. CEO total compensation as printed in Jazz Pharmaceuticals plc's own proxy. As printed: 19,151,558. View filing ↗
  • The Cooper Companies, Inc., Section 10b CEO total. DEF 14A, filed 2026-02-24. CEO total compensation as printed in The Cooper Companies, Inc.'s own proxy. As printed: 16,051,141. View filing ↗
  • Hologic, Inc., Section 10b CEO total. 10-K/A, filed 2026-01-22. CEO total compensation as printed in Hologic, Inc.'s own proxy. As printed: 15,931,655. View filing ↗
  • Agilent Technologies, Inc., Section 10b CEO total. DEF 14A, filed 2026-02-06. CEO total compensation as printed in Agilent Technologies, Inc.'s own proxy. As printed: 12,827,236. View filing ↗
  • Steris plc, Section 10b CEO total. DEF 14A, filed 2026-06-11. CEO total compensation as printed in Steris plc's own proxy. As printed: 11,508,522. View filing ↗
  • Perrigo plc, Section 10b CEO total. DEF 14A, filed 2026-03-20. CEO total compensation as printed in Perrigo plc's own proxy. As printed: 9,042,603. View filing ↗
  • Bio-Rad Laboratories, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-25. CEO total compensation as printed in Bio-Rad Laboratories, Inc.'s own proxy. As printed: 7,995,841. View filing ↗
  • West Pharmaceutical Services, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-12. CEO total compensation as printed in West Pharmaceutical Services, Inc.'s own proxy. As printed: 7,190,876. View filing ↗
  • Mettler-Toledo International Inc., Section 10b CEO total. DEF 14A, filed 2026-03-18. CEO total compensation as printed in Mettler-Toledo International Inc.'s own proxy. As printed: 6,741,212. View filing ↗
  • Catalent, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2023-12-15. CEO total compensation as printed in Catalent, Inc.'s own proxy. As printed: 6,583,672. View filing ↗
  • Section 10a, Agilent Technologies, Inc. reciprocity. DEF 14A. Agilent Technologies, Inc. names Catalent, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗